Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Publish Ahead of Print published online ahead of print August 6, 2007
DOI: 10.2337/db07-0822
This Article
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-0822v1
56/11/2677    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medarova, Z.
Right arrow Articles by Moore, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medarova, Z.
Right arrow Articles by Moore, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Non-invasive Magnetic Resonance Imaging of Microvascular Changes in Type 1 Diabetes

Zdravka Medarova, Ph.D.1, Gerardo Castillo, Ph.D.2, Guangping Dai, Ph.D.1, Elijah Bolotin, Ph.D.2, Alexei Bogdanov, Ph.D.3, and Anna Moore, Ph.D.1

1 Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston MA
2 PharmaIN, Ltd. (www.pharmain.com), Seattle WA, 98122, USA
3 Department of Radiology, University of Massachusetts Medical School, Worcester, MA

Correspondence: amoore{at}helix.mgh.harvard.edu

Objective:The pathogenesis of type 1 diabetes (T1D) involves autoimmune lymphocytic destruction of insulin-producing beta-cells and metabolic dysregulation. An early biomarker of pancreatic islet damage is islet microvascular dysfunction. Alterations in vascular volume, flow, and permeability have been reported in numerous models of T1D. Consequently, the ability to non-invasively monitor the dynamics of pancreatic microvasculature would aid in early diagnosis and permit the assessment, design, and optimization of individualized therapeutic intervention strategies.

Research Design and Methods:Here, we employed the long-circulating paramagnetic contrast agent, PGC-GdDTPA-F (protected graft copolymer covalently linked to gadolinium-diethylenetriaminepentaacetic acid residues and labeled with fluorescein), for the noninvasive semi-quantitative evaluation of vascular changes in a streptozotocin (STZ)-induced mouse model of T1D. Diabetic animals and non-diabetic controls were monitored by magnetic resonance imaging (MRI) after injection of PGC-GdDTPA-F.

Results:Our findings demonstrated a significantly greater accumulation of PGC-GdDTPA-F in the pancreata of diabetic animals, as compared to controls. MRI permitted the in vivo semi-quantitative assessment and direct visualization of the differential distribution of PGC-GdDTPA-F in diabetic and control pancreata. Ex vivo histology revealed extensive distribution of PGC-GdDTPA-F within the vascular compartment of the pancreas, as well as considerable leakage of the probe into the islet interstitium. By, contrast, in non-diabetic controls, PGC-GdDTPA-F was largely restricted to the pancreatic vasculature at the islet periphery.

Conclusions:Based on these observations we conclude that in the STZ model of T1D, changes in vascular volume and permeability associated with early stages of the disease, can be monitored non-invasively and semi-quantitatively by MRI.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.